Journal
CELL
Volume 168, Issue 4, Pages 707-723Publisher
CELL PRESS
DOI: 10.1016/j.cell.2017.01.017
Keywords
-
Categories
Funding
- Parker Institute for Cancer Immunotherapy
- NIH/NCI [R01 CA1633793, R35 CA197633, P01 CA168585]
- Cancer Prevention Research in Texas (CPRIT) [RP120108]
- Ressler Family Fund
- Garcia-Corsini Family Fund
- Samuels Family Fund
- Grimaldi Family Fund
- Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant [SU2C-AACR-DT1012]
- American Society of Clinical Oncology (ASCO)
- Tower Cancer Research Foundation Grant
- Hope Foundation
- UCLA KL2 Award
Ask authors/readers for more resources
Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available